Dynamic modeling of cortisol reduction after inhaled administration of fluticasone propionate

Shashank Rohatagi, Alan Bye, Christine Falcoz, Alison E. Mackie, Bernd Meibohm, Helmut Möllmann, Hartmut Derendorf

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Fluticasone propionate (FP) is o new corticosteroid that has been developed for the treatment of asthma. The compound has a very high receptor affinity, 18 times that of dexamethasone. After inhalation, FP is systemically available because of inhaled bioavailability. In healthy subjects this may lead to measurable systemic effects, such as cortisol reduction. A clinical study was conducted in 12 healthy volunteers to determine the systemic effects after inhaled administration of single 500- μg, 1,000-μg, and 2.000-μg doses of FP. Blood samples were collected over a 24-hour period after administration. Concentrations of FP and cortisol were measured in plasma by immunoassay. Cortisol reduction was chosen as the pharmacodynamic parameter. A novel linear release rate model was used to parameterize the cortisol data. The pharmacokinetics of FP were linear over the dose range studied. The cortisol release parameters were determined from baseline data (before drug administration). Based on these results, the E50 values for cortisol reduction were then determined for each dose of FP. The average E50 was 0.134 ng/mL for total FP concentrations and 0.013 ng/mL for unbound FP concentrations: these results were not dose dependent. These in viva pharmacodynamic values measured in healthy subjects are in good agreement with the relatively high receptor affinity of FP.

Original languageEnglish (US)
Pages (from-to)938-941
Number of pages4
JournalJournal of Clinical Pharmacology
Volume36
Issue number10
DOIs
StatePublished - Jan 1 1996
Externally publishedYes

Fingerprint

Hydrocortisone
Healthy Volunteers
Fluticasone
Immunoassay
Pharmaceutical Preparations
Inhalation
Dexamethasone
Biological Availability
Adrenal Cortex Hormones
Asthma
Pharmacokinetics

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Dynamic modeling of cortisol reduction after inhaled administration of fluticasone propionate. / Rohatagi, Shashank; Bye, Alan; Falcoz, Christine; Mackie, Alison E.; Meibohm, Bernd; Möllmann, Helmut; Derendorf, Hartmut.

In: Journal of Clinical Pharmacology, Vol. 36, No. 10, 01.01.1996, p. 938-941.

Research output: Contribution to journalArticle

Rohatagi, Shashank ; Bye, Alan ; Falcoz, Christine ; Mackie, Alison E. ; Meibohm, Bernd ; Möllmann, Helmut ; Derendorf, Hartmut. / Dynamic modeling of cortisol reduction after inhaled administration of fluticasone propionate. In: Journal of Clinical Pharmacology. 1996 ; Vol. 36, No. 10. pp. 938-941.
@article{85643b1426b44dff81745be4eb5ac7b7,
title = "Dynamic modeling of cortisol reduction after inhaled administration of fluticasone propionate",
abstract = "Fluticasone propionate (FP) is o new corticosteroid that has been developed for the treatment of asthma. The compound has a very high receptor affinity, 18 times that of dexamethasone. After inhalation, FP is systemically available because of inhaled bioavailability. In healthy subjects this may lead to measurable systemic effects, such as cortisol reduction. A clinical study was conducted in 12 healthy volunteers to determine the systemic effects after inhaled administration of single 500- μg, 1,000-μg, and 2.000-μg doses of FP. Blood samples were collected over a 24-hour period after administration. Concentrations of FP and cortisol were measured in plasma by immunoassay. Cortisol reduction was chosen as the pharmacodynamic parameter. A novel linear release rate model was used to parameterize the cortisol data. The pharmacokinetics of FP were linear over the dose range studied. The cortisol release parameters were determined from baseline data (before drug administration). Based on these results, the E50 values for cortisol reduction were then determined for each dose of FP. The average E50 was 0.134 ng/mL for total FP concentrations and 0.013 ng/mL for unbound FP concentrations: these results were not dose dependent. These in viva pharmacodynamic values measured in healthy subjects are in good agreement with the relatively high receptor affinity of FP.",
author = "Shashank Rohatagi and Alan Bye and Christine Falcoz and Mackie, {Alison E.} and Bernd Meibohm and Helmut M{\"o}llmann and Hartmut Derendorf",
year = "1996",
month = "1",
day = "1",
doi = "10.1002/j.1552-4604.1996.tb04761.x",
language = "English (US)",
volume = "36",
pages = "938--941",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",
number = "10",

}

TY - JOUR

T1 - Dynamic modeling of cortisol reduction after inhaled administration of fluticasone propionate

AU - Rohatagi, Shashank

AU - Bye, Alan

AU - Falcoz, Christine

AU - Mackie, Alison E.

AU - Meibohm, Bernd

AU - Möllmann, Helmut

AU - Derendorf, Hartmut

PY - 1996/1/1

Y1 - 1996/1/1

N2 - Fluticasone propionate (FP) is o new corticosteroid that has been developed for the treatment of asthma. The compound has a very high receptor affinity, 18 times that of dexamethasone. After inhalation, FP is systemically available because of inhaled bioavailability. In healthy subjects this may lead to measurable systemic effects, such as cortisol reduction. A clinical study was conducted in 12 healthy volunteers to determine the systemic effects after inhaled administration of single 500- μg, 1,000-μg, and 2.000-μg doses of FP. Blood samples were collected over a 24-hour period after administration. Concentrations of FP and cortisol were measured in plasma by immunoassay. Cortisol reduction was chosen as the pharmacodynamic parameter. A novel linear release rate model was used to parameterize the cortisol data. The pharmacokinetics of FP were linear over the dose range studied. The cortisol release parameters were determined from baseline data (before drug administration). Based on these results, the E50 values for cortisol reduction were then determined for each dose of FP. The average E50 was 0.134 ng/mL for total FP concentrations and 0.013 ng/mL for unbound FP concentrations: these results were not dose dependent. These in viva pharmacodynamic values measured in healthy subjects are in good agreement with the relatively high receptor affinity of FP.

AB - Fluticasone propionate (FP) is o new corticosteroid that has been developed for the treatment of asthma. The compound has a very high receptor affinity, 18 times that of dexamethasone. After inhalation, FP is systemically available because of inhaled bioavailability. In healthy subjects this may lead to measurable systemic effects, such as cortisol reduction. A clinical study was conducted in 12 healthy volunteers to determine the systemic effects after inhaled administration of single 500- μg, 1,000-μg, and 2.000-μg doses of FP. Blood samples were collected over a 24-hour period after administration. Concentrations of FP and cortisol were measured in plasma by immunoassay. Cortisol reduction was chosen as the pharmacodynamic parameter. A novel linear release rate model was used to parameterize the cortisol data. The pharmacokinetics of FP were linear over the dose range studied. The cortisol release parameters were determined from baseline data (before drug administration). Based on these results, the E50 values for cortisol reduction were then determined for each dose of FP. The average E50 was 0.134 ng/mL for total FP concentrations and 0.013 ng/mL for unbound FP concentrations: these results were not dose dependent. These in viva pharmacodynamic values measured in healthy subjects are in good agreement with the relatively high receptor affinity of FP.

UR - http://www.scopus.com/inward/record.url?scp=0029849213&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029849213&partnerID=8YFLogxK

U2 - 10.1002/j.1552-4604.1996.tb04761.x

DO - 10.1002/j.1552-4604.1996.tb04761.x

M3 - Article

VL - 36

SP - 938

EP - 941

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

IS - 10

ER -